M

MaxCyte Inc
NASDAQ:MXCT

Watchlist Manager
MaxCyte Inc
NASDAQ:MXCT
Watchlist
Price: 4.11 USD 1.23%
Market Cap: 433.5m USD
Have any thoughts about
MaxCyte Inc?
Write Note

MaxCyte Inc
Free Cash Flow

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

MaxCyte Inc
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
M
MaxCyte Inc
NASDAQ:MXCT
Free Cash Flow
-$25.4m
CAGR 3-Years
-33%
CAGR 5-Years
-18%
CAGR 10-Years
N/A
Thermo Fisher Scientific Inc
NYSE:TMO
Free Cash Flow
$7.8B
CAGR 3-Years
-1%
CAGR 5-Years
15%
CAGR 10-Years
14%
Danaher Corp
NYSE:DHR
Free Cash Flow
$5B
CAGR 3-Years
-11%
CAGR 5-Years
8%
CAGR 10-Years
5%
Mettler-Toledo International Inc
NYSE:MTD
Free Cash Flow
$888.6m
CAGR 3-Years
3%
CAGR 5-Years
13%
CAGR 10-Years
11%
Agilent Technologies Inc
NYSE:A
Free Cash Flow
$1.4B
CAGR 3-Years
2%
CAGR 5-Years
10%
CAGR 10-Years
10%
IQVIA Holdings Inc
NYSE:IQV
Free Cash Flow
$2B
CAGR 3-Years
-6%
CAGR 5-Years
24%
CAGR 10-Years
20%
No Stocks Found

MaxCyte Inc
Glance View

Market Cap
432.8m USD
Industry
Life Sciences Tools & Services

MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. The company is headquartered in Gaithersburg, Maryland. The company went IPO on 2016-03-29. The firm is focused on providing enabling platform technologies to advance cell-based research and development, as well as next-generation cell therapeutic discovery, development and commercialization. The firm has developed and commercialized its Flow Electroporation platform, which facilitates complex engineering of a variety of cells. Its ExPERT platform is based on its Flow Electroporation technology, which has been designed to address the cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. Its ExPERT platform consists of three instruments, which are known as the ATx, STx and GTx. The firm has also developed CARMA, a therapeutic platform based on transfecting mRNA into unstimulated cells for the development of immune cell therapies.

MXCT Intrinsic Value
3.37 USD
Overvaluation 18%
Intrinsic Value
Price
M

See Also

What is MaxCyte Inc's Free Cash Flow?
Free Cash Flow
-25.4m USD

Based on the financial report for Dec 31, 2023, MaxCyte Inc's Free Cash Flow amounts to -25.4m USD.

What is MaxCyte Inc's Free Cash Flow growth rate?
Free Cash Flow CAGR 5Y
-18%

Over the last year, the Free Cash Flow growth was 24%. The average annual Free Cash Flow growth rates for MaxCyte Inc have been -33% over the past three years , -18% over the past five years .

Back to Top